Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
KidneyCancer
Interventions
DRUG

5-Flourouracil, Interferon-a, IL-2 and Thalidomide

"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."

Trial Locations (3)

87108

Lovelace Sandia Health Systems Dept of Hematology, Albuquerque

87131

University of New Mexico, Albuquerque

Unknown

New Mexico Cancer Care Associates, Santa Fe

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT00277017 - Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter